Peptide Graded

Apraglutide

Is Apraglutide safe?

Dropout 3.6% vs 1.9% on placebo; polyp concern open

BSome human evidenceIn clinical trialsas of 2026-10-27

In STARS, 2.7% of patients on apraglutide and 1.9% on placebo stopped treatment because of adverse events. The most frequent adverse events on apraglutide were nausea (13.6%), headache (12.7%) and central catheter infections (12.7%). Abdominal pain, diarrhea and bloating occurred at similar rates to placebo. About 7% of patients in both arms had injection-site reactions. 1

GLP-2 analogues promote growth of gut tissue. So the whole class carries a theoretical concern that polyps or tumours could grow faster in the gut. STARS included colonoscopy checks. They found gut polyps in 3.6% of apraglutide patients and 3.8% of placebo patients, and no cancers. Too few patients have taken apraglutide for too short a time to settle the question. Long-term safety data do not exist. 1

Read the full Apraglutide page

More on Apraglutide

Citations

  1. Joly 2026, Clinical Gastroenterology and Hepatology: STARS phase 3 trial of once-weekly apraglutide in SBS-IF doi.org
  2. Verbiest 2024, Clinical Nutrition: open-label phase 2 metabolic balance study of apraglutide in SBS-IF with colon-in-continuity doi.org
  3. ClinicalTrials.gov: NCT07742735, second phase 3 trial of apraglutide clinicaltrials.gov

Reference information only, not medical advice. Drawn from the Apraglutide article, fact-checked against the cited sources. No dosing anywhere on this site.